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Cancer is a complex disease marked by uncontrolled cell growth and invasion. These
processes are driven by the accumulation of genetic and epigenetic alterations that
promote cancer initiation and progression. Contributing to genome changes are the
regulation of oxidative stress and reactive species-induced damage to molecules and
organelles. Redox regulation, metabolic plasticity, autophagy, and mitophagy play
important and interactive roles in cancer hallmarks including sustained proliferation,
activated invasion, and replicative immortality. However, the impact of these processes
can differ depending on the signaling pathways altered in cancer, tumor type, tumor
stage, and/or the differentiation state. Here, we highlight some of the representative
studies on the impact of oxidative and nitrosative activities, mitochondrial bioenergetics,
metabolism, and autophagy and mitophagy in the context of tumorigenesis. We discuss
the implications of these processes for cellular activities in cancer for anti-cancer-based
therapeutics.As the name suggests, reactive oxygen species (ROS) are
molecules that contain oxygen and are highly reactive. ROS
include hydroxyl radical, hydrogen peroxide, and superox-
ide. The reaction of superoxide and the free radical nitric
oxide also produces peroxynitrite, a potent oxidant. The
molecules are produced by specific enzymatic pathways
including the mitochondrial electron transport chain NOX/ology, University of Ala
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g).
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/by-nc-nd/4.0/).nicotinamide adenine dinucleotide phosphate oxidases and
nitric oxide synthases [1e7]. These reactive species can act
as cell signaling molecules and also cause nonspecific
posttranslational modification of proteins if domain-
dependent control of their action is lost [8e13]. Under such
circumstances, the irreversible modification of lipid, DNA,
and proteins can accumulate in the cell and inactivate thebama at Birmingham, Biomedical Research Building II, 901 19th
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organelles with which they are associated [14,15]. The
maintenance of a redox homeostasis is then critical to both
reductive and oxidative stress occurring when regulation of
these pathways is lost [16]. Also, cancer initiation and pro-
gression are significantly impacted by redox signaling as
well as redox stress [17].
Cellular metabolism is essential to generate adenosine
triphosphate to provide the energy needed for multiple
cellular functions. Such functions include DNA replication,
transcription, translation, protein transport, assembly of
multi-molecule complexes and organelles, cell mobility,
and enzymatic reactions. In addition, the metabolites
generated are building blocks for synthesis of DNA, RNA,
and other essential cellular constituents. Metabolic pro-
grams are controlled at the levels of uptake of nutrients
from extracellular space, glycolysis, and mitochondrial
respiration. These metabolic functions can be regulated by
reactive species and can also, in turn, regulate cellular
redox status.
Autophagy and mitophagy are lysosome-mediated degra-
dation of intracellular lipids, proteins, and organelles [18e21].
This degradation can serve to clear reactive species-induced
damage to these molecules and cellular compartments. The
processes are highly regulated by more than 30 proteins and
many signaling pathways [21], which can include redox
signaling itself as well as cellular metabolic programs [22e33].
The integration of these cellular activities plays important
roles in cancer initiation and progression and will be dis-
cussed in this review.Reactive species, signaling, and stress in cancer
initiation and progression
DNA damage by reactive species can be carcinogenic as
represented by the link between cigarette smoking and
increased risk of cancer [34e37]. Cigarette smoke contains
reactive species such as nitric oxide, hydrogen peroxide, and
peroxynitrite [34,35], and cigarette smokers exhibit
increased oxidative damage as evidenced by elevated 8-
hydroxy-20deoxyguanosine (8-OHdG) levels [36,37]. The
involvement of ROS in transformation mediated by onco-
genes or tumor suppressor loss has also been demonstrated.
For example, exogenous expression of oncogenic, constitu-
tively active H-RasG12V or Myc leads to ROS-dependent
transformation or mitogenic activities [38e41]. Down-
regulation of tumor suppressor genes such as p53 also leads
to increased intracellular ROS, DNA oxidation, and mutation
rate. Reactive nitrogen species also contribute to tumor
growth as demonstrated by studies suggesting the impor-
tance of nitric oxide for cancer growth and tumor initiating
cell maintenance [42e46]. In converse, antioxidant-related
drugs and molecules have been shown to inhibit tumor
initiation. For example, the antioxidant N-acetylcysteine
attenuates lymphomas in p53 knockout mice [47,48]. A
transcription factor, critical for upregulation of antioxidantenzymes, nuclear factor (erythroid-derived 2) factor 2 (Nrf2),
also attenuates cancer initiation similar to the antioxidant
proteins it upregulates [49e56]. Together, these data suggest
a pro-tumorigenic role for reactive species and a benefit for
antioxidant-based therapies.
While reactive species can be pro-tumorigenic, their
contribution to tumor biology is diverse and needs to be
carefully considered prior to the development of novel ther-
apeutic approaches. Evidence indicates that the role of ROS
and antioxidants can differ depending on cell type or disease
state. For example, mouse embryonic fibroblasts expressing
endogenous K-RasG12V have lower levels of ROS as detected
in the dichlorofluorescein fluorescence assay [57]. In this
model, another indicator of oxidative stress, the glutathione
(GSH) disulfide (oxidized GSH) to GSH (reduced glutathione;
GSH) ratio, is also decreased in Nrf2-dependent fashion [57]. In
tumor cells, high levels of antioxidant production through
mechanisms such as upregulation of Nrf2 can provide sur-
vival advantages and resistance to chemotherapy
[17,56,58e63]. Indeed, dual inhibition of the antioxidants
glutathione and thioredoxin synergistically decreases tumor
cell growth in vivo [167]. Overexpression of the anti-apoptotic
factor Bcl2 also causes lymphomas in mice and humans
without altering the rate of peroxide generation while atten-
uating oxidative damage to lipid membranes [64]. These
studies highlight the complexity of the role of reactive species
in cancer, which may vary depending on the genetic, epige-
netic, and microenvironmental variation present in tumors.
Thus, it may be difficult to make broad conclusions regarding
the use of antioxidants for cancer therapy in the context of the
diverse initiation and progression mechanisms of the disease
[17,55,56,62].Metabolic programming in cancer initiation and
progression
Obesity increases the risk for various cancers, consistent
with a close link of whole body metabolism to cancer pre-
disposition [65,66]. At the cellular level, it has been long
noted that metabolic programs in cancer cells differ from
normal cells [67]. Recent studies identified diverse mecha-
nisms of metabolic plasticity in cancer cells. These include
increased glucose uptake in most tumors [68e71], elevated
glycolytic intermediates due to the expression of the pyru-
vate kinase M2 isoform [72e76], increased pentose phos-
phate pathway activities associated with transketolase
isoform TKTL1 elevation [77,78], increased glutamine
catabolism [79,80], and increased use of lactate as a fuel in
selective tumors [81]. Signaling pathways and molecules,
such as Akt and Myc that are known to play important roles
in cancer, regulate the expression of glucose and glutamine
transporters, glucose metabolism enzymes, glutamine
metabolism, and mitochondrial biogenesis [82e92]. Thus, it
is becoming increasingly apparent that the pro-survival and
pro-proliferative roles of oncogenic signals are strongly
linked to changes in cellular metabolism and mitochondrial
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attenuates mitochondrial respiration and stimulates
glycolysis with mechanisms including regulation of subunit
I of cytochrome c oxidase, synthesis of cytochrome c oxi-
dase 2, hexokinase 2, glucose transporters, phosphoglyc-
erate mutase 1, and TP53-induced glycolysis and apoptosis
regulator [93e98]. In human glioblastomas [99e101] and
acute myeloid leukemia [102], somatic mutations of iso-
citrate dehydrogenases alter metabolism by converting a-
ketoglutarate to 2-hydroxyglutarate, which in turn leads to a
hypermethylation phenotype [103,168]. The causal rela-
tionship of altered metabolism in tumorigenesis has also
been suggested by the finding that germline mutations of
succinate dehydrogenase and fumarate hydratase cause
hereditary tumors, likely mediated by multifaceted mecha-
nisms including altered gene expression, altered cell
signaling, increased mutagenesis, or upregulation of hyp-
oxia inducible factor 1 alpha (HIF1a) [104e107]. The data
have led to increasing recognition that genetic mutations
and metabolic changes in cancer are linked and required for
the development and progression of the disease.Autophagy and mitophagy in cancer initiation
and progression
Autophagy senses cellular metabolic status, as well as various
stress signals [29,108]. More than 30 proteins coordinate the
autophagic processes, generating autophagosomes from
essentially all membrane sources from the cell. Key signaling
pathways include AMP-activated protein kinase (AMPK)-
mammalian target of rapamycin (mTOR) pathways, Beclin-
VPS34 complexes, ATG3, 4, 5, 6, 7, 8, 12, and 16 that are
involved in autophagosomal formation, and adaptor proteins
sequestosome 1 (SQSTM1)/p62 and NDP52 that recognize
ubiquitinated targets. Perturbations of these pathways have
been shown to contribute to tumorigenesis [109]. For example,
mTOR inhibitors tuberous sclerosis complex-1/2 are tumor
suppressors [110]. Beclin/ATG6 deficiency has been found to
be associated with human breast, ovarian, and prostate tu-
mors [111]; Beclin þ/ mice develop tumors in endocrine tis-
sues [112,113]. ATG4C, ATG5, and ATG7 genetic disruptions
have also been found to develop liver adenomas or exhibit
increased tumorigenesis in response to carcinogens in mice
[114,115].
One regulator of autophagic flux associated with cancer is
GABA(A) receptor-associated protein-like 1 (GABARAPL1).
Lower levels of GABARAPL1 have been associated with poor
outcome for liver and breast cancer patients [116,117], and
GABARAPL1 is suggested to be a tumor suppressor through
the inhibition of Wnt [118,119]. GABARAPL1 interacts with
the Wnt/b-catenin signaling activator segment polarity pro-
tein disheveled homolog Dvl-2 and plays an important role in
Dvl-2 degradation. Data indicate that knockdown of
GABARAPL1 in breast cancer cells promotes proliferation and
invasion in association with decreased autophagic flux and
decreased lysosome numbers [120]. Although therequirement for Wnt in this effect is not known, Wnt
signaling is well-established as a regulator of breast cancer
initiation and metastasis [121,122], suggesting the attenuated
GABARAPL1-mediated repression of Wnt signaling promotes
breast cancer development and progression. Together, these
data strongly suggest that a better understanding of the
critical regulators of autophagy cellular transformation and
tumor growth is important.
The above evidence indicates that autophagic deficits
promote tumorigenesis as autophagy is required to guard
against oxidative damage to the genome [23]. However, as
multiple mechanisms are involved in both autophagy regu-
lation and tumorigenesis, the connection between autophagy
and tumor biology can be complex. For example, ablation of
FIP200, a downstream target of mTOR inhibition and cofactor
of ATG1-ATG13 activation, has been shown to inhibit mam-
mary tumorigenesis [123]. In established tumors, autophagy
may provide a survival advantage to the tumor cells in
nutrient-deprived conditions and support chemoresistance
[124]. Thus, autophagy inhibitors, such as chloroquine, have
been tested in cancer therapy [125,126].
Mitophagy or autophagy of mitochondria is required to
eliminate dysfunctional mitochondria to maintain appro-
priate metabolic and cell survival signals [32]. One key
mediator of mitophagy linked to cancer is the putative
tumor suppressor gene Parkin. Parkin is located at a chro-
mosomal fragile site and loss is associated with tumors of
the lung, breast, brain, ovary, pancreas, and colon [127e134].
In animal models, deletion of exon 3 of Parkin also promotes
the development of spontaneous hepatic tumors [131]. The
mechanisms through which Parkin acts as a tumor sup-
pressor continue to be elucidated, but it is known that Par-
kin translocates to the mitochondria as a consequence of
loss of membrane potential, leading to ubiquitination of
mitochondrial proteins and recruitment of p62-LC3 and
autophagosomes to the mitochondria [29,32,135e137]. It
regulates the ubiquitination of multiple mitochondrial pro-
teins [138] with important targets being identified as the
mitochondria fusion regulator Mitofusin 2 [139] and the
mitochondria migration regulator mitochondrial rhoGTPase
(Miro) [140]. Recent evidence suggesting the potential
involvement of these Parkin targets in cancer further dem-
onstrates the importance of mitophagy and mitochondrial
function in cancer [141e144].
Parkin recruitment to promote mitophagy can be regu-
lated by Bcl2/adenovirus E1B 19 kDa-interacting protein 3
(BNip3), and very recent evidence demonstrates that BNip3
integrates mitophagy and apoptosis signaling in cancer
[145,146]. BNip3 utilizes its BH3 domain to inhibit pro-
survival Bcl2 family members, and thereby activating
apoptosis while also increasing mitophagy by binding
autophagosomes through an LC3 interacting region. BNip3
loss has been associated with progression of breast cancer
to metastasis through a mechanism thought to involve
retention of dysfunctional mitochondria [147]. BNip3 loss
prevents normal mitophagy, leading to elevated levels of
ROS. In this breast cancer model system, increased ROS
resulted in elevated levels of HIF1a and its target genes. The
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consistent with a Warburg effect. Thus, the data directly
linked loss of BNip3 regulated mitophagy to changes in
metabolism promoting cancer progression. As BNip3 itself is
a well-known HIF target gene, these data also demonstrate
the complex interactions between the pathways regulating
and being regulated by mitophagy [148].
On the other hand, in established tumors, an increased
mitophagy associated with an increased autophagy may also
provide a survival advantage to the tumor cells in nutrient
deprived or hypoxic conditions and support chemoresistance.
However, it is unclear whether increased mitophagy without
increasing general autophagy occurs in advanced tumors, and
whether specific inhibition of mitophagy sensitizes estab-
lished tumors to chemotherapies.Integration of reactive species, metabolic
programs, and autophagy in cancer
The relationship between reactive species and metabolic
programs and its role in cancer have been extensively studied.
Reactive speciesmodification of DNA, lipids, or protein clearly
impacts cell metabolism and proliferation [149e151]. Exam-
ples include the oxidative modification of mitochondrial DNA
and mitochondrial proteins, as well as the induction of cell
signaling and transcription pathways that are tumorigenic
[41,152,153]. Conversely, mitochondrial dysfunction plays a
direct role inmodulating cellular redox status [154,155] as well
as generation of NADH and reduced GSH by the pentose
phosphate pathway [153].
The relationship between reactive species and autophagy
is also emerging as being important in cancer biology [156].
Reactive species regulation of autophagy has been demon-
strated by thiol modification of ATG4 cysteines and signaling
through the ataxia-telangiectasia mutated-liver kinase B1-
AMPK-mTOR pathway [157,158]. Reactive species modifica-
tion of Kelch-like ECH-associated protein 1 (KEAP1) leads to
upregulation of the antioxidant regulating transcription factor
Nrf2 and increased levels of autophagy adaptor protein
SQSTM1/p62 [159]. Conversely, autophagy regulates KEAP1
levels and homeostasis of the KEAP1-Nrf2 pathway, thereby
regulating cellular redox status [160].
The interactions among reactive stress, metabolism, and
autophagy in cancer initiation and progression are complex.
Strong evidence indicated these interactions in cancer. For
example, the major nutrient-sensing Akt-AMPK-mTOR
pathway is regulated by reactive stress and is a direct
regulator of autophagy [158]. In pancreatic ductal adeno-
carcinoma cells, increased nuclear import of micro-
phthalmia/transcription factor E family of transcription
factors enhances autophagy-lysosomal catabolic function,
maintains intracellular amino acid pools, and thereby sup-
porting cell proliferation [161]. The tumor suppressor gene
p53 has been shown to be activated by nutrient and oxida-
tive stress while its activation also plays a role in metabolichomeostasis and autophagy by a variety of transcriptional
as well as cytosolic mechanisms [162]. Recent studies also
suggested that the covalent attachment of N-acetylglucos-
amine (O-GlcNAc) is not only involved in nutrient sensing
and cancer metabolism [163], but may also play a role in
regulating autophagy [164e166]. These data demonstrate
that there are multiple cross regulation mechanisms for
ROS, autophagy, and metabolic signals in cancer.Conclusion
Existing evidence supports the general concept that cancer
initiation can be facilitated by changes in reactive species,
autophagy, and metabolism. These changes may include
increased reactive species modification of mitogenic
signaling, reactive damage to DNA and proteins, decreased
autophagic and mitophagic clearance of damaged macro-
molecules and organelles, and altered metabolic substrate
availabilities and usages. Tumor cells with established
genome mutations or rearrangements are highly dependent
on metabolic plasticity to sustain proliferation, antioxidants,
autophagy, andmitophagy to gain survival advantages. Cross-
regulation of reactive species production and elimination,
mitochondrial bioenergetics and glucose metabolism, and
autophagy and mitophagy add additional complexity of the
biology of tumorigenesis. Detailed or individualized mecha-
nisms in specific tumors and specific stages of tumorigenesis
and progression can be diverse and are still being intensively
investigated. Studies on the regulation of mitochondrial bio-
energetics, metabolism, autophagy and mitophagy, and how
reactive species integrate these regulations in different can-
cers will continue to provide important insights into cancer
biology and therapeutics.
Normal cells are dependent on reactive species for cell
signaling, mitochondria and glycolysis for energy, metabo-
lites for biosynthesis, and autophagy for clearance of
excessive or damaged macromolecules and organelles.
Dysregulated reactive species generation and deficient
autophagy contribute to tumorigenesis by enhancing muta-
genesis and genome instability. Once tumors are estab-
lished, tumor cells with upregulated autophagy and Nrf2-
mediated antioxidant production may gain a survival
advantage in low nutrient and hypoxic conditions. In addi-
tion, metabolic activities, such as mitochondrial biogenesis,
glycolytic activities, and glutamine utilization, are upregu-
lated to help sustain the energy demand for tumor growth.
Understanding the coordination of these activities during
tumorigenesis and progression is important for the preven-
tion and management of cancer [Fig. 1].Financial support and sponsorship
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